Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Integrates Compugen Database; Seeks to Be One-Stop Shop

SAN FRANCISCO, Jan. 8 - Embarking on a program to expand the breadth of its content offerings, Gene Logic has struck a distribution deal with Compugen, Gene Logic CEO Mark Gessler said in a presentation here on Tuesday.


Terms of the deal call for Gene Logic to integrate Compugen's Gencarta human genome and proteome database into its GeneExpress gene-expression and phenotype platform.


Gene Logic wants to make additional content-enhancing agreements similar to the Compugen deal, Gessler said. He would not specify what companies or products might me targets.


"We're going to want to add other's content," he said. "Pharma wants a one-stop shopping stop and a preferred vendor. We want to be the de facto and leading player on the desktop."


Though he wouldn't disclose the financial terms of the deal, Gessler said that Compugen's Gencarta content allowed Gene Logic to expand the capabilities for its customers.


Gencarta was "the right kind of user interface for our clients," Gessler told investors and analysts at the 20th annual JPMorgan H&Q Healthcare Conference, which runs here through Thursday. "Not too dense, not too simple. We want to hit the guys at the benchtop working day in and day out."


The Compugen database will be offered to customers as an add-on for "less than $500,000" and will be available at the end of the second quarter this year, he said.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.